CNBX Pharmaceuticals Inc. (OTCPK: CNBX)
Health Care · Pharmaceuticals · US
$0.00
+3.45% today · -62.5% 1Y
CNBX Pharmaceuticals Inc. (OTCPK: CNBX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $240.87K and employs 1 people.
Over the last twelve months the share price has lost 62.5%, trading between 0.00 and 0.00.
Tweenvest scores CNBX Pharmaceuticals Inc. across four factors: quality 8/100. Its strongest factor is quality.
CNBX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $240.87K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.61B
- Employees
- 1
- Next earnings
- —
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
- ISIN
- US13764M2098
- Founded
- 2004
- Listed since
- Sep 4, 2007
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.